TNON (Tenon Medical Inc.) experienced a momentum-driven short squeeze following a reverse stock split, underpinned by genuinely solid fundamental news. On August 10, 2026, Tenon completed a 1-for-35 reverse split, reducing total outstanding shares to fewer than 700,000 and leaving a public float of approximately 600,000 shares (one of the smallest floats among Nasdaq-listed companies). This factor alone creates the conditions for explosive intraday price movements. These dynamics were bolstered by fundamentals that provided the necessary narrative.
In its Q2 2026 earnings report, Tenon announced revenue of $1.3 million, a 127% year-over-year increase, accompanied by a 232% rise in gross profit and significant gross margin expansion, climbing from 43% in the same period the previous year to 64%. Training events for physicians and distributors increased by 98% in the first half of 2026 compared to the second half of 2025, directly translating into a record monthly case volume in July for its Catamaran sacroiliac joint fusion system. Additionally, in July, the company received FDA 510(k) clearance for an enhanced version of the Catamaran system; modifications to the instrumentation are expected to reduce per-procedure costs and further expand margins starting in the third quarter.
A $4.2 million public offering, also closed in July, provided additional funds to sustain operations through 2027. For a stock with a float of 600,000 shares, the convergence of post-reverse-split dynamics and a strong fundamental catalyst creates the perfect scenario for explosive intraday moves: when massive volume floods in and the sell-side liquidity (the “ask”) is exhausted, the price has no choice but to skyrocket vertically.
